I think UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 (Exact nam ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2021 Earnings Conference Call May 5, 2021 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Senior Vice President, Clinical development Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Robyn Karnauskas - Truist Securities Ted Tenthoff - Piper Sandler Alethia Young - Cantor Yigal Nochomovitz - Citi Michael Yee - Jefferies Peter Lawson - Barclays Tazeen ...

I think UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 (Exact na ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2020 Earnings Conference Call February 24, 2021 5:00 PM ET Corporate Participants Scott Wolchko - President and Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Srikripa Devarakonda - Truist Securities Alethia Young - Cantor Michael Schmidt - Guggenheim Yigal Nochomovitz - Citi Mara Goldstein - Mizuho Matt Biegler - Oppenheimer Caro ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or o ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2020 Earnings Conference Call November 5, 2020 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Edward Dulac - Chief Financial Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Matt Biegler - Oppenheimer Kelsey Goodwin - Guggenheim Securities Ben Burnett - Stifel Biren Amin - Jefferies Daina Graybosch - SVB ...

I think UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdict ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q2 2020 Earnings Conference Call August 5, 2020 5:30 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Robyn Karnauskas - Truist Securities Kelsey Goodwin - Guggenheim Securities Daina Graybosch - SVB Leerink Mara Goldstein - Mizuho Peter Lawson - Barclays Matt Biegler - Oppenh ...

I think UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERA ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2020 Earnings Conference Call May 11, 2020 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Wayne Chu - Senior Vice President, Clinical Development Conference Call Participants Ted Tenthoff - Piper Sandler Robyn Karnauskas - SunTrust Robinson Jim Birchenough - Wells Fargo Alethia Young - Cantor Daina Graybosch - SVB Leerink David Nierengarten - Wedbush Securities Biren Amin - Jefferies Mara Goldstein - Mizuho Ben Burnett - Stifel ...